Here's What You May Have Missed About Alcon (ALC)

By Ken Smith • Thursday, April 20 12:07 • Permanent Link

Join us for a quick overview of Alcon, a Ophthalmic Goods company whose shares moved 0.8% today. Here are some facts about the stock that should help you see the bigger picture:

Alcon has moved -11.1% over the last year, and the S&P 500 logged a change of -5.4%
ALC has an average analyst rating of buy and is -14.87% away from its mean target price of $83.55 per share
Its trailing earnings per share (EPS) is $0.67
Alcon has a trailing 12 month Price to Earnings (P/E) ratio of 106.2 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.95 and its forward P/E ratio is 24.1
The company has a Price to Book (P/B) ratio of 1.8 in contrast to the S&P 500's average ratio of 2.95
Alcon is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $866,750,016.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.